Preclinical and Phase I Clinical Studies of KW-2450, a Dual IGF-1R/IR Tyrosine Kinase Inhibitor, in Combination With Lapatinib and Letrozole
Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758835918786858
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2018
Authors
Publisher
SAGE Publications